| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aclaris Therapeutics, Inc. (ACRS) has 12 insiders with recent SEC Form 4 filings, including 24 buys and 1 sell. ACRS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 13.95M | $67.80M | -300,000 | |
| COO | 336.3K | $1.63M | - | |
| CEO | 274.8K | $1.34M | - | |
| CFO | 160.4K | $779.6K | - | |
| Other | 155.0K | $753.5K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | Leonard Braden Michael61 | 10% Owner | Sell | 300,000 | $4.53 | $1,359,000.00 | -2.1% | - | - | |
| Nov 19, 2024 | Mehra Anand | Director | Buy | 666,666 | $2.25 | $1,499,998.50 | +1,537% | -49.9% | -46.4% | |
| Aug 5, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 373,569 | $1.27 | $472,756.74 | +1.3% | +75.0% | +25.0% | |
| Jul 31, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 273,730 | $1.31 | $359,010.19 | +1.0% | +27.6% | +14.2% | |
| Jul 22, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 154,722 | $1.30 | $201,808.11 | +0.4% | -9.0% | +21.8% | |
| Jul 5, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 352,397 | $1.15 | $405,894.27 | +0.9% | -0.8% | +21.7% | |
| Jul 1, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 1,543,434 | $1.13 | $1,742,074.99 | +3.2% | 0.0% | +22.6% | |
| Jun 18, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 545,000 | $1.15 | $628,206.00 | +1.6% | +5.3% | +25.7% | |
| Jun 13, 2024 | Leonard Braden Michael61 | 10% Owner | Buy | 1,611,200 | $1.11 | $1,781,896.79 | +4.0% | -0.8% | +23.5% | |
| Mar 4, 2024 | Powell Andrew Kenneth William | Director | Buy | 14,500 | $1.24 | $17,955.00 | +39.0% | -16.8% | +54.4% |